The value of early treatment in patients with haemophilia and inhibitors
Abstract number: PP-MO-606
Kavakli1 K., Yesilipek2 A., Antmen3 B., Aksu4 S., Balkan1 C., Yilmaz1 D., Kupesiz2 A., Sasmaz3 I., Lindgren5 P., Mesterton5 J.
11Ped. Hematology, Ege University Hospital, Izmir 22Ped. Hematology, Akdeniz University Hospital, Antalya 33Ped. Hematology, Cukurova University Hospital, Adana 44Hematology, Hacettepe University Hospital, Ankara, Turkey 55i3 Innovus, i3 Innovus, Stockholm, Sweden
How-to-cite Kavakli K, Yesilipek A, Antmen B, Aksu S, Balkan C, Yilmaz D, Kupesiz A, Sasmaz I, Lindgren P, Mesterton J. The value of early treatment in patients with haemophilia and inhibitors. Journal of Thrombosis and Haemostasis 2009; Volume 7, Supplement 2: Abstract PP-MO-606
Objectives: Haemophilia is placing a significant economic burden on the healthcare systems. Even though there is some evidence that a delay in treatment initiation leads to a larger number of injections being required, total costs of treating haemophilia patients with inhibitors have never been formally linked to the time to initiation of treatment. The objective of this study was to assess the relationship between time to initiation of treatment with rFVIIa (NovoSeven¯) and time to resolution of the bleeding episode as well as total costs in mild to moderate bleeding episodes in patients with congenital haemophilia and inhibitors.
Methods: A multicentric retrospective analysis of patients’ charts was conducted in Turkey. Data were extracted for 129 bleeding episodes from 16 patients at 4 study centers. Data were collected on patient characteristics, time to treatment initiation, time to bleeding resolution and resource use related to the bleeding, including medical treatments, hospitalization, diagnostic tests and lost production. A GLM regression analysis was used to analyze the impact of time to treatment initiation on health care costs, and time to bleeding resolution.
Results: The average total cost per bleeding episode was 16441 YTL. Controlling for other factors such as patient age, weight and bleeding characteristics, longer time to treatment initiation had a significant effect on total costs of the bleeding (P-value: 0.005) and time to bleeding resolution (P-value: 0.053).
Conclusion: These results show that treatment with rFVIIa should be initiated as soon as possible after the onset of the bleeding in order to minimize costs and optimize outcomes.
Disclosure of interest: K.Kavakli, C.Balkan, D.Yilmaz, A.Yesilipek, A.Kupesiz, B.Antmen, I.Sasmaz, S.Aksu (Research Grant from Novo Nordisk for data collection) P. Lindgren, J. Mesterton (Research Grant from Novo Nordisk for data analysis).
